1. Introduction {#sec1}
===============

To date, percutaneous transluminal coronary angioplasty (PTCA) and stenting have been the important strategies for the treatment of coronary heart diseases (CHD). However, the incidence of restenosis (RS) is at a high level within 6 months after surgery \[[@B1]\]. Although the drug-eluting stent has significantly reduced the RS incidence, the application of drug-eluting stents still has some limitations. Thus, the prevention and treatment of RS have become a hot topic in the field of interventional cardiology.

PTCA may cause damage to the vascular endothelial cells (VECs), aggregation of inflammatory cells, activation of platelets, and release of some cytokines such as interleukin-1 (IL-1), interferon (IFN), fibroblast growth factor (FGF), platelet-derived factor (PDGF), and transforming growth factor-*β* (TGF-*β*) \[[@B2]\]. These can lead to the migration and hyperplasia of vascular smooth muscle cells (VSMCs) finally resulting in vascular stenosis \[[@B3]\]. TGF-*β*, with many biological activities, has been confirmed to be an important cytokine regulating the production and deposition of extracellular matrix (ECM) \[[@B4]\].

TGF-*β*1 is a growth factor with hormone-like activity, has the molecular weight of about 25 kDa, and can form dimmers via disulfide bond. Studies showed, at 6 h after balloon injury, the TGF-*β*1 expression began to rise and the increased TGF-*β*1 sustained for 14 days \[[@B5]\]. TGF-*β*1 may stimulate the proliferation of neointimal cells and induce the synthesis and remodeling of ECM resulting in vascular restenosis \[[@B6]\]. *In vivo* study has demonstrated that TGF-*β*1 could promote the hyperplasia of neointima \[[@B7]\]. Tranilast was found to effectively reduce the thickening of neointima and restenosis at the stent via reducing the TGF-*β*1 activity or directly inhibit TGF-*β*1 expression \[[@B8], [@B9]\]. In addition, TGF-*β*1 was demonstrated to stimulate the synthesis of fibronectin in the VSMCs via the Smad3 signaling pathway, leading to the deposition of ECM in the neointima \[[@B10]\], which contributes to the RS. These findings demonstrate that neointimal formation is closely related to the TGF-*β*1/Smad3 signaling pathway, but the exact mechanism is still unclear.

In our previous study, the adenoviral vectors expressing antisense Smad3 were constructed and used to transfect VSMCs collected from rats undergoing vascular injury. Results revealed that inhibition of Smad3 expression could compromise the proliferation of VSMCs \[[@B11]\]. In the rat carotid artery balloon injury model, inhibition of Smad3 expression was found to reduce the thickening of vascular intima and decrease the ratio of intima area to media area (I/M) \[[@B12]\]. In the present study, adenoviral vectors expressing antisense Smad3 were used to transfect VSMCs of rats undergoing balloon injury *in vitro* or directly injected into rats receiving balloon injury followed by detection of collagen I and III (components of ECM). This study aimed to investigate the role of TGF-*β*1/Smad3 signaling pathway in the neointimal formation and our findings may provide evidence for the prevention and treatment of postoperative RS.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Male Sprague-Dawley (SD) rats aged 6 weeks (weight: 350--450 g) were purchased from the Shanghai Slac Laboratory Animal Co., Ltd (Production license: SCXK \[Hu\] 2004-0005; Use license: SYXK\[Hu\]2007-0007). The construction, packaging, amplification, and purification of blank adenovirus and adenovirus expressing antisense Smad3 \[[@B13]\] were purchased from the Shanghai Ji Kaiji Chemical Technology Company Limited (Shanghai, China). Adenoviral vectors were prepared at 6 × 10 pfu/mL before study.

2.2. *In Vitro* Culture and Transfection of VSMCs from Rats Receiving Carotid Artery Balloon Injury {#sec2.2}
---------------------------------------------------------------------------------------------------

The 2F catheter was used to induce left carotid artery balloon injury in above rats according to previously reported methods \[[@B14]\]. Two weeks later, tissue block culture method was employed to culture the VSMCs in DMEM containing 10% fetal bovine serum (FBS). Immunohistochemistry was done to identify the VSMCs. The VSMCs from injured artery (injury group) and normal VSMCs (normal group) were included. The cells of passage 3 were used in the following experiments.

In the *in vitro*experiment, the VSMCs from injured artery and divided into three groups and included: experiment group (cells transfected with adenovirus expressing antisense Smad3), negative control group (cells transfected with blank adenovirus), and blank control group (cells collected from rats with balloon injury but without any treatment). Transfection was performed with the multiplicity of infection (MOI) of 100 pfu, and detection was done 72 h later.

2.3. *In Vivo* Experiment and Sample Collection {#sec2.3}
-----------------------------------------------

The rat balloon injury model was established in 90 rats according to previously reported methods \[[@B14]\]. In the blank control group, rats underwent carotid artery balloon injury alone; in the experiment group, rats received carotid artery balloon injury and subsequently the adenovirus expressing antisense Smad3 (0.5 mL; 6 × 10 pfu/mL) was injected via the external carotid artery; in the negative control group, rats received carotid artery balloon injury, and subsequently the blank adenovirus solution (0.5 mL; 6 × 10 pfu/mL) was injected via the external carotid artery. During the injection, the tension of common carotid artery was maintained. At 30 min after perfusion, the external carotid artery was clamped but the blood flow of the internal and common carotid artery was assured. Following wound closure, the rats were given *ad libitum* assess to food and water.

At 1 day, 3 days, 1 week, 2 weeks, 1 month, and 3 months after balloon injury, rats were sacrificed. The left common carotid artery was collected, washed in normal saline, fixed in 4% paraformaldehyde, embedded in paraffin and sectioned. A fraction of tissues were stored in liquid nitrogen and then at −80°C for real-time PCR. Before sample collection, 5 mL of blood was collected from the heart and centrifuged. The serum was obtained and stored at −80°C for use.

2.4. Real-Time PCR {#sec2.4}
------------------

Total RNA was extracted by using Trizol reagent. Then, 2 *μ*g of RNA was used for reverse transcription into cDNA. Real-time PCR was done in the MX3000P thermal cycler (Applied Biosystems). The primers are shown in [Table 1](#tab1){ref-type="table"}. The conditions for PCR were 95°C for 5 min and 40 cycles of 95°C for 30 s, 58°C for 30 s, and 72°C for 45 s. *β*-actin served as an internal reference and the expression of target genes was normalized to that of *β*-actin.

2.5. Detection with Enzyme Linked Immunosorbent Assay (ELISA) {#sec2.5}
-------------------------------------------------------------

The contents of TGF-*β*1 and type I and III collagen in the culture medium and serum were measured with ELISA according to manufacturer\'s instructions.

2.6. Pathological Examinations {#sec2.6}
------------------------------

The paraffin-embedded tissues were sectioned and HE staining was performed. The morphology of blood vessel wall was observed under a light microscope. Image analysis system (Image pro Plus 4.5) was used to measure the lumen area and intima area.

2.7. Statistical Analysis {#sec2.7}
-------------------------

All data were expressed as means ± SD, and SPSS version 11.0 was employed for statistical analysis. One way analysis of variance was done to compare the means among different groups. A value of *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Expression of TGF-*β*1, Smad3, and Type I and III Collagen in VSMCs from Rats with Arterial Balloon Injury {#sec3.1}
---------------------------------------------------------------------------------------------------------------

Significant differences were found in the expressions of TGF-*β*1, Smad3, type I and III collagen between the injury group and normal group (*P* \< 0.05). Results from real-time PCR are shown in [Figure 1(a)](#fig1){ref-type="fig"}. In the injury group, the mRNA expressions of TGF-*β*1, Smad3, type I and III collagen were increased by 21%, 32%, 41%, and 46%, respectively, as compared to the normal group. Results from ELISA are shown in [Figure 1(b)](#fig1){ref-type="fig"}. Results demonstrated that the contents of TGF-*β*1, Smad3, and type I and III collagen in the injury group were 81 ± 6.71, 56 ± 5.21, 37 ± 2.37, and 77 ± 6.13 ng/mL, respectively, which were significantly different from those in the normal group.

3.2. Smad3 Expression in VSMCs Transfected with Adenovirus Expressing Antisense Smad3 {#sec3.2}
-------------------------------------------------------------------------------------

In the *in vitro* study, the mRNA expression of Smad3 in the experiment group was markedly lowered by 47% when compared to the negative control group ([Figure 2](#fig2){ref-type="fig"}) (*P* \< 0.01), but no marked difference was noted between the negative control group and blank control group (*P* \> 0.05).

3.3. Type I and III Collagen Expression in VSMCs Transfected with Adenovirus Expressing Antisense Smad3 {#sec3.3}
-------------------------------------------------------------------------------------------------------

In the *in vitro* experiment, the type I and III collagen expression in the experiment group were dramatically reduced by 35% and 47%, respectively, when compared with negative control group (*P* \< 0.05) ([Figure 3(a)](#fig3){ref-type="fig"}). ELISA revealed the contents of type I and III collagen in the experiment group were 21 ± 1.34 ng/mL and 55 ± 2.74 ng/mL, respectively, which were markedly lower than those in the negative control group (*P* \< 0.05) ([Figure 3(b)](#fig3){ref-type="fig"}). However, significant differences in the contents of type I and III collagen were not found between the negative control group and the blank control group (*P* \> 0.05).

3.4. Expression of Type I and III Collagen In Vivo {#sec3.4}
--------------------------------------------------

Previous study showed the Smad3 expression in the experiment group was significantly reduced at 1 day, 3 days, and 2 weeks after injury as compared to the negative control group (*P* \< 0.05), thereafter decreased gradually and reached a minimal level at 3 months after injury (0.96 ± 0.24) \[[@B12]\]. No significant difference in the Smad3 expression was found between the experiment group and the negative control group at 3 months after injury (*P* \> 0.05). In the present study, the type I and III collagen was also measured *in vivo*. Our findings revealed the type I collagen expression was dramatically inhibited at 3 days, 1 week and 2 weeks after injury when compared with the negative control group (*P* \< 0.05) (Figures [4(a)](#fig4){ref-type="fig"}-[4(b)](#fig4){ref-type="fig"}), but there was no significant difference between experiment group and negative control group at 3 months after injury (*P* \> 0.05). In addition, the type III collagen expression was dramatically reduced at 3 days, 1 week, and 2 weeks after injury when compared with the negative control group (*P* \< 0.05) (Figures [4(c)](#fig4){ref-type="fig"}-[4(d)](#fig4){ref-type="fig"}), but no pronounced difference was found between the experiment group and the negative control group at 3 months after injury (*P* \> 0.05).

3.5. Effect of *In Vivo* Transfection on Vascular Lumen {#sec3.5}
-------------------------------------------------------

HE staining was performed to observe the morphology of blood vessels. A previous study showed the ratio of I/M in the experiment group was markedly lower than that in the negative control group (*P* \< 0.05) at 1 day, 2 weeks, and 3 months after injury, but there was no significant difference between the negative control group and the blank control group at above three time points (*P* \> 0.05) \[[@B12]\]. In the present study, we also measured the vascular lumen area and intima area and results are shown in [Table 2](#tab2){ref-type="table"}. Results showed the lumen area at 2 weeks and 3 months after injury in the experiment group was significantly increased as compared to the negative control group (*P* \< 0.05), but marked difference was absent at 1 week after injury (*P* \> 0.05). The intima area in the injury group was dramatically reduced at 2 weeks and 3 months after injury as compared to the negative control group, but no significant difference was found between them at 1 week after injury (*P* \> 0.05).

4. Discussion {#sec4}
=============

Percutaneous coronary intervention (PCI) has been the most effective strategy in the treatment of CHD, but the incidence of RS is as high as 35--50% at 3--6 months after injury \[[@B15]\], which has been a pivotal factor affecting the therapeutic efficacy of PCI and become a focus in the field of CHD. Overdeposition of ECM is a key step in the vascular intimal hyperplasia and lumen stenosis. In humans, VSMCs account for only 11% of neointima during the RS and the remaining components are ECM \[[@B16]\]. Currently, studies have demonstrated that inhibition of ECM deposition is a novel strategy for the prevention of post-PTCA restenosis \[[@B17]\]. TGF-*β*1 can promote the proliferation and migration of SMCs in the vascular intima and facilitate the formation of ECM resulting in RS \[[@B4]\].

TGF-*β*1 can bind to receptors on the smooth muscle and fibroblasts and then exert its biological effects via inducing the phosphorylation of signal regulatory proteins. The down-stream proteins of TGF-*β*1 include ERK, MAPK, JNK, and Smad3 \[[@B6]\], and Smad3 has been confirmed as a definite and important regulator at the down-stream of TGF-*β*1 \[[@B18], [@B19]\]. Following vascular injury, the TGF-*β*1 is up-regulated \[[@B20]\] and then stimulates the fibronectin synthesis via the Smad3 signaling pathway, which may increase the deposition of ECM in the neointima \[[@B10]\]. In addition, TGF-*β*1 can induce the transformation of fibroblasts into *α*-SMA expressing myofibroblasts \[[@B21]\] and promote the secretion of ECM, which have been found to play important roles in the vascular remodeling.

Members of Smad family play critical roles in the TGF-*β* signal transduction and different Smads mediate the signal transduction of different members of Smad family. Studies showed the gene transcription and apoptosis could be regulated by TGF-*β*/Smad2/3-Smad4 \[[@B22]\]. In the SMCs, TGF-*β*1 can increase the phosphorylation of Smad2 and Smad3, which then form heterogeneous trimmers with Smad4. The heterogeneous trimmers then translocate into the nucleus and bind to the Smad-related DNA sequence, leading to the transcription of fibronectin, type I collagen and connective tissue growth factor, which may finally result in vascular RS. Multiple *in vivo* models \[[@B23]--[@B26]\] revealed that the protein expression of Smads was upregulated at the site of arterial injury. Studies on carotid artery injury \[[@B27]\] demonstrated an upregulated expression of Smad3 but not Smad2 in both medial and neointimal cells. In humans, the Smad3 expression at the site of RS was higher than that in the atherosclerotic plaques \[[@B28]\]. The majority of cells expressing Smad3 at high level also express the markers of proliferation. The Smad3 treated artery was found to have larger lumen than that in the control group, which indicates that Smad3 involves in the vascular remodeling \[[@B27]\].

The establishment of carotid artery injury in rats is relatively simple in operation and has relatively high success rate. In addition, the pathophysiology of intimal hyperplasia following injury, and changes in the expression of related cytokines and proteins are similar to those in humans. Thus, this animal model has been widely used in the investigation of postoperative vascular RS \[[@B14]\]. In our previous study \[[@B12]\], the Smad3 expression in the blood vessels was detected at different time points after injury. Results showed the Smad3 expression increased dramatically at 1 day after injury (*P* \< 0.05) and the high Smad3 expression maintained for 2 weeks (*P* \< 0.05) but returned to nearly normal level at 3 months after injury, which were consistent with previous findings \[[@B26]\]. In the present study, the VSMCs were collected from rats undergoing balloon injury, and results ([Figure 1](#fig1){ref-type="fig"}) showed the expressions of TGF-*β*1, Smad3, and type I and III collagen were markedly increased when compared with the normal group (*P* \< 0.05).

To further investigate the role of TGF-*β*1/Smad3 signaling pathway in the VSMCs induced RS, adenovirus expressing antisense Smad3 was constructed and used to transfect VSMCs from rats with balloon injury and the mRNA expression of Smad3 was detected. Results demonstrated that the mRNA expression of Smad3 was reduced by about 50% ([Figure 2](#fig2){ref-type="fig"}).

Collagen is the most abundant component of ECM in the vascular wall and accounts for more than 50% of vascular wall with stenosis. To date, 13 types of collagen have been identified of which 6 were found to be closely related to the vascular wall (I, III, IV, V, VI, and VIII). Among 6 types of collagen, types I, III, and IV have been found to be closely related the vascular RS. Type I and III collagen belongs to the interstitial collagen and accounts for 80\~90% of collagen in the blood vessels. In the present study, our results showed, in VSMCs transfected with adenovirus expressing antisense Smad3, the TGF-*β*1/Smad3 expression was reduced, and type I and III collagen expression also decreased ([Figure 3](#fig3){ref-type="fig"}). Further *in vivo* study revealed, at 2 weeks and 3 months after injury, the neointima area reduced but the lumen area increased after injection of adenovirus expressing antisense Smad3 ([Table 2](#tab2){ref-type="table"}). These findings suggest that to block the TGF-*β*1/Smad3 signaling pathway may reduce the neointimal hyperplasia to a certain extent, which may attribute to the reduced generation of ECM and type I and III collagen.

Madri et al. \[[@B29]\] first noted increased immunostaining for TGF-*β*1 in the intimal regions of rat carotid arteries 10 weeks after balloon catheter injury. Majesky et al. \[[@B30]\] found that VSMCs had significantly enhanced TGF-*β*1 levels 6 h after carotid injury in rats, being 5--7-fold above baseline within 24 h, and remaining elevated for 2 weeks as intimal thickening occurred. In porcine coronary arteries \[[@B31]\], balloon angioplasty injury resulted in significantly elevated active TGF-*β*1 levels between 2 h and 7 days after intervention, returning to baseline 28 days later. Nikol et al. \[[@B5], [@B32]\] found expression of transforming growth factor-*β*1 is increased in human vascular RS lesions.

At early stage of acute injury, the TGF-*β*1 expression is significantly increased, which may be related to the thrombosis in the acute phase and release of a large amount of growth factors by platelets and local inflammation. At early stage of intima injury, the TGF-*β*1 expression increases as a response involving in the repair of blood vessels. At 2 weeks after injury, the serum TGF-*β*1 level decreased to a certain extent, but was still at a high level when compared with the control group. At this time, the TGF-*β*1 further exerts biological effects to promote the proliferation of SMCs and facilitate the deposition of ECM. In the present study, the type I and III collagen was significantly reduced at 3 days and 2 weeks after injury ([Figure 4](#fig4){ref-type="fig"}), but the changes in lumen area and intima area were the most evident at 2 weeks and 3 months after injury in the antisense Smad3 group ([Table 2](#tab2){ref-type="table"}).

Our findings suggest that the transfection with adenovirus expressing antisense Smad3 can inhibit the Smad3 expression, which then suppresses the collagen metabolism, reduces the ECM deposition, and inhibits the neointimal proliferation to a certain extent. Our findings provide evidence for the gene therapy of RS following PTCA.

![Expressions of TGF-*β*, Smad3, and type I and III collagen in VSMCs from rats undergoing carotid artery balloon injury. SD rats aged 6 weeks were employed to establish the postcarotid artery balloon injury RS model. Two weeks after injury, tissue block culture was performed to culture the VSMCs in DMEM containing 10% FBS. These cells were divided into normal group and injury group, and immunohistochemistry for *α*-SMA was done to identify the VSMCs. VSMCs of passage 3 were collected for the following experiments. (a) quantitative RT-PCR. The mRNA expressions of TGF-*β*1, Smad3, and type I and III collagen were independently normalized to that of *β*-actin as the relative expression. The mRNA expression of target genes in the normal group was defined as the baseline level, and that in the injury group was normalized to that in the normal group as fold change which was then used for delineation. Data were expressed as mean ± SD. (b) The culture medium was collected, and ELISA was performed to measure the contents of TGF-*β*1, type I and III collagen. ^▲^*P* \< 0.05, ^■^*P* \< 0.01 versus normal group.](JBB2012-965953.001){#fig1}

![Smad3 expression in VSMCs transfected with adenovirus expressing antisense Smad3 *in vitro*. Following injury, VSMCs were collected and divided into 3 groups. In the antisense Smad3 group, cells were transfected with adenovirus expressing antisense Smad3; in the negative control group, cells were transfected with blank adenovirus; in the blank control group, cells received no treatment. Transfection was done with adenovirus at an MOI of 100 pfu. Three days later, total RNA was extracted from each group and RT-PCR was performed. The mRNA expression of Smad3 was normalized to that of *β*-actin. The mRNA expression of Smad3 in the blank control group served as the baseline level, and the mRNA expression of Smad3 in other groups was normalized to that in the blank control group as the fold change which was used for delineation. Data were expressed as mean ± SD. ^▲^*P* \< 0.05, ^■^*P* \< 0.01 versus negative control group.](JBB2012-965953.002){#fig2}

![Expressions of type I and III collagen in VSMCs transfected with adenovirus expressing antisense Smad3 *in vitro*. Total RNA was extracted for RT-PCR. The culture medium was collected, and ELISA was performed to measure the contents of type I and III collagen. (a) mRNA expression of type I and III collagen in three groups; (b) contents of type I and III collagen in three groups. The mRNA expression of type I and III was normalized to that of *β*-actin as the relative expression. Data were expressed as mean ± SD. ^▲^*P* \< 0.05, ^■^*P* \< 0.01 versus negative control group.](JBB2012-965953.003){#fig3}

![Expressions of type I and III collagen in VSMCs following injection of adenovirus expressing antisense Smad3 *in vivo*. Ninety SD rats were randomly assigned into blank control group, experiment group, and negative control group. In all groups (*n* = 5 per group), rats were sacrificed at 1 day, 3 days, 1 week, 2 weeks, 1 month, and 3 months after injury followed by sample collection. Total RNA was extracted for the detection of mRNA expressions of type I and III collagen with quantitative PCR (a, c). In addition, the serum was also collected from rats followed by detection of type I and III collagen contents with ELISA (b, d). (a) mRNA expression of type I collagen in different groups; (b) content of type I collagen in the serum of different groups; (c) mRNA expression of type III collagen in different groups; (d) content of type III collagen in the serum of different groups. The mRNA expressions of type I and III collagen were normalized to that of *β*-actin. The mRNA expressions of type I and III collagen in the blank control group served as the baseline levels, and those in other groups were normalized to those in the blank control group as the fold change which was used for delineation. Data were expressed as mean ± SD. ^▲^*P* \< 0.05, ^■^*P* \< 0.01 versus negative control group.](JBB2012-965953.004){#fig4}

###### 

Primers for real-time PCR.

  Genes                                       Sequences                                   Expected size
  ------------------------------------------- ------------------------------------------- ---------------
  TGF-*β*1                                    Forward 5^′^-ACTCCCAGAAAAGCAAGCAA-3^′^      211 bp
  Reverse 5^′^-CGAGCAGGAATGAGAAGAGG-3^′^                                                  
                                                                                          
  Smad3                                       Forward 5^′^-CATTACCATCCCCAGGTCAC-3^′^      102 bp
  Reverse 5^′^-CGTAACTCATGGTGGCTGTG-3^′^                                                  
                                                                                          
  Collagen I                                  Forward 5^′^-CCC TGA AGT CAG CTG CAT-3^′^   193 bp
  Reverse 5^′^-ATA TTC TTC TGG GCA GAA-3^′^                                               
                                                                                          
  Collagen III                                Forward 5^′^-TGGTCCTCAGGGTGTAAAGG-3^′^      232 bp
  Reverse 5^′^-GTCCAGCATCACCTTTTGG-3^′^                                                   
                                                                                          
  *β*-actin                                   Forward 5^′^-CTGTCCCTGTATGCCTCTG-3^′^       217 bp
  Reverse 5^′^-TGTCACGCACGATTTCC-3^′^                                                     

###### 

Vascular lumen area and intima area in different groups.

                     Lumen area (mm^2^)   Intima area (mm^2^)                                                   
  ------------------ -------------------- --------------------- ---------------- ------------- ---------------- ----------------
  Blank control      0.39 ± 0.05          0.31 ± 0.03           0.14 ± 0.05      0.07 ± 0.01   0.12 ± 0.04      0.39 ± 0.03
  Negative control   0.40 ± 0.07          0.33 ± 0.03           0.17 ± 0.02      0.08 ± 0.02   0.13 ± 0.02      0.42 ± 0.01
  Antisense Smad3    0.40 ± 0.08          0.40 ± 0.06^▲^        0.21 ± 0.03^▲^   0.06 ± 0.02   0.07 ± 0.01^▲^   0.17 ± 0.04^▪^

Note: ^▲^*P* \< 0.05 and ^▪^*P* \< 0.01 versus negative control.

[^1]: Academic Editor: Richard Tucker
